# Cadence Neuroscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cadence-neuroscience

- Industry: Medical Devices & Equipment
- Headquarters: Sammamish, US
- Website: www.cadenceneuro.com
- Total disclosed funding: $29M
- Latest round: Series B (Feb 21, 2023)
- Investors on record: 7

## About

Based in the US, Cadence Neuroscience, Inc. specializes in developing innovative therapeutic solutions to address drug-resistant focal epilepsy through advanced technology and cutting-edge research.Founded in 2017 and headquartered in Sammamish, US, Cadence Neuroscience, Inc. focuses on the treatment of epilepsy. The company has raised a total of USD 26.03 mn through multiple funding rounds, with the most recent round being a Series B funding on February 21, 2023, led by Lumira Ventures alongside various other investors. Kent Leyde serves as the CEO.Cadence Neuroscience focuses on developing advanced therapeutic solutions for drug-resistant focal epilepsy through its investigational Biomarker Targeting Stimulation (BTS) device therapy. This offering utilizes pioneering research from Mayo Clinic and comprises an implantable device designed to deliver targeted electrical stimulation to specific areas of the brain. The system includes advanced technologies that facilitate personalized therapy by optimizing device placement and stimulation parameters tailored to the individual patient’s needs. The trial stimulation phase allows clinicians to identify responsive patients prior to implanting a permanent device. Cadence aims to serve patients suffering from epilepsy, primarily in North America and Europe, as it conducts clinical studies to broaden access to its innovative treatment options.Cadence Neuroscience's revenue generation model is predicated on direct transactions with healthcare providers and institutions that adopt its BTS device therapy for the treatment of epilepsy. The company engages in partnerships with hospitals and medical facilities, facilitating the implementation of its technology through structured agreements. These partnerships involve a combination of upfront device costs and ongoing service fees associated with the monitoring and adjustment of the therapy post-implantation. Revenue is primarily derived from the sale of the BTS device and associated services, which are aligned with their commitment to personalized patient care. As the company advances through regulatory approvals and expands its clinical studies, it aims to establish a sustainable revenue stream from its flagship therapeutic offerings.In February 2023, Cadence Neuroscience, Inc. raised USD 26.03 mn in Series B funding, led by Lumira Ventures, aimed at completing pivotal clinical studies and pursuing FDA clearance for its BTS device therapy. The company plans to leverage the recent funding to enhance its product development and regulatory processes, with an objective to expand its market presence in North America and Europe by targeting new healthcare partnerships and refining its clinical offerings.

## Funding rounds

- Series B, Feb 21, 2023, $26M — Mayo Clinic Ventures, F-Prime Capital, JAZZ Venture Partners, LivaNova PLC, Spectrum Financial Services, Lumira Ventures, Angelini Ventures
- Series A, Sep 9, 2019, $3M — Mayo Clinic Ventures, JAZZ Venture Partners

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series A, Series B
- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- LivaNova PLC — Series B
- Spectrum Financial Services — Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series B
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series B